Breast cancer patients with obesity or Type 2 diabetes who used GLP-1s had lower all-cause mortality and risk of recurrence, according to a study published May 11 in JAMA Network Open.
Researchers from Richmond, Va.-based VCU Massey Comprehensive Cancer Center analyzed TriNetX Collaborative Network data from 841,831 patients diagnosed with breast cancer at 68 healthcare organizations between April 1, 2006, and April 1, 2023.
Here are three notes from the study:
- The study included three patient groups:
- 1,610 patients with obesity to analyze GLP-1 use versus nonuse
- 2,323 patients with Type 2 diabetes to analyze for GLP-1 use versus use of insulin or metformin
- 4,052 patients with Type 2 diabetes to analyze GLP-1 use versus sodium-glucose cotransporter 2 inhibitors
- Among patients with obesity and those with Type 2 diabetes, GLP-1 use was associated with a lower risk of all-cause mortality and recurrence.
There was no significant difference in all-cause mortality and recurrence between patients who used GLP-1s and those who used sodium-glucose cotransporter 2 inhibitors.
- “Further studies are needed to understand the biological mechanisms, if any, between [GLP-1s] and breast cancer outcomes,” VCU Massey said in a May 11 news release. “The research team intends to further evaluate these correlations through randomized clinical trials.”
Read the full study here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
